首页> 外文期刊>CNS drug reviews >TAT-GDNF in neurodegeneration and ischemic stroke.
【24h】

TAT-GDNF in neurodegeneration and ischemic stroke.

机译:TAT-GDNF在神经变性和缺血性中风中的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

The delivery of proteins across the blood-brain barrier is severely limited by their size and biochemical properties. Numerous peptides have been characterized in recent years that prevent neuronal death in vitro, but cannot be used therapeutically, since they do not cross cell membrane barriers. It has been shown in the 1990s that the HIV TAT protein is able to cross cell membranes even when coupled with larger peptides. It appears, therefore, that TAT fusion proteins may enter the brain, even when used systemically. Indeed, the systemic delivery of a TAT protein linked with glial-derived neurotrophic factor (GDNF) successfully transduced central nervous system (CNS) neurons in mice. When administered after optic nerve transection and focal cerebral ischemia, TAT-GDNF protected retinal ganglion cells and brain neurons from cell death, elevated tissue Bcl-XL levels and attenuated the activity of the executioner caspase-3. These findings demonstrate the in vivo efficacy of fusion proteins in clinically relevant disease models, raising hopes that neuroprotection may become eventually feasible in human patients.
机译:跨血脑屏障的蛋白质输送受到蛋白质大小和生化特性的严重限制。近年来,已表征了许多肽,它们可在体外预防神经元死亡,但由于它们不穿过细胞膜屏障,因此无法用于治疗。在1990年代已经证明,即使与较大的肽偶联,HIV TAT蛋白也能够穿过细胞膜。因此,即使系统使用TAT融合蛋白,也可能会进入大脑。确实,与胶质细胞源性神经营养因子(GDNF)连接的TAT蛋白的系统性递送成功地在小鼠中转导了中枢神经系统(CNS)神经元。当在视神经横断和局灶性脑缺血后给药时,TAT-GDNF可以保护视网膜神经节细胞和脑神经元免受细胞死亡,组织Bcl-XL水平升高并削弱the子手caspase-3的活性。这些发现证明了融合蛋白在临床相关疾病模型中的体内功效,提高了对神经保护在人类患者中最终可行的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号